HCM stock news · rev $548.5M
HCM (HCM) common stock.
This HCM news page leads with what HCM filed — not a scraped headline mill.
No cached 8-K sentence for HCM yet. We will not pad this page with generic market recap.
Latest reported HCM revenue for 2025-12-31 was $548.5M. Net income was $456.9M. Revenue was down 13.0% from 2024-12-31 to 2025-12-31. HCM currently screens at market cap $0.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the HCM stock page; for the tape open the quote page.
HCM cached headlines
- HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy — Yahoo Finance
- Panmure and Cavendish reiterate buy on Hutchmed after GSK deal — Yahoo Finance
- HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal — Yahoo Finance
- HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy — Yahoo Finance
- HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China — Yahoo Finance
- HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma — Yahoo Finance
- HUTCHMED shares rise as lung cancer drug trial hits key targets — Yahoo Finance
- HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® — Yahoo Finance
- HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ... — Yahoo Finance
- HUTCHMED H1 Earnings Call Highlights — Yahoo Finance
- HUTCHMED Reports 2026 Interim Results — Yahoo Finance
- HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification — Yahoo Finance
Not investment advice.